148 related articles for article (PubMed ID: 2788659)
21. Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells.
Ellis TM; Fisher RI
J Immunol; 1989 Apr; 142(8):2949-54. PubMed ID: 2467946
[TBL] [Abstract][Full Text] [Related]
22. Differential activation of lymphokine-activated killer cells with different surface phenotypes by cultivation with recombinant interleukin 2 or T-cell growth factor in gastric cancer patients.
Koyama S; Ebihara T; Fukao K; Osuga T
Jpn J Cancer Res; 1989 Feb; 80(2):150-7. PubMed ID: 2498249
[TBL] [Abstract][Full Text] [Related]
23. IL-4 inhibits IL-2-mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures.
Spits H; Yssel H; Paliard X; Kastelein R; Figdor C; de Vries JE
J Immunol; 1988 Jul; 141(1):29-36. PubMed ID: 2454260
[TBL] [Abstract][Full Text] [Related]
24. Characteristics of interleukin-6-enhanced lymphokine-activated killer cell function.
Iho S; Shau HY; Golub SH
Cell Immunol; 1991 Jun; 135(1):66-77. PubMed ID: 2018984
[TBL] [Abstract][Full Text] [Related]
25. [Analysis of cytolytic activity and cell surface phenotypes of lymphokine activated killer cells stimulated with R-IL 2 and an anti-CD 3 antibody].
Kikuchi T; Sakai H; Nakamura N; Watanabe M; Ohno T
No To Shinkei; 1990 Jun; 42(6):575-80. PubMed ID: 2119634
[TBL] [Abstract][Full Text] [Related]
26. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
[TBL] [Abstract][Full Text] [Related]
27. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
[TBL] [Abstract][Full Text] [Related]
28. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
Nio Y; Zighelboim J; Berek JS; Bonavida B
Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516
[TBL] [Abstract][Full Text] [Related]
29. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
30. Phenotypic characterization of murine lymphokine-activated killer cells.
Owen-Schaub LB; Abraham SR; Hemstreet GP
Cell Immunol; 1986 Dec; 103(2):272-86. PubMed ID: 2879640
[TBL] [Abstract][Full Text] [Related]
31. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.
Kasid A; Bell GI; Director EP
J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414
[TBL] [Abstract][Full Text] [Related]
32. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
Hermann GG; Zeuthen J; Claƫsson MH
Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
[TBL] [Abstract][Full Text] [Related]
33. Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity.
Kaufmann Y; Levanon M; Davidsohn J; Ramot B
J Immunol; 1987 Aug; 139(3):977-82. PubMed ID: 3496395
[TBL] [Abstract][Full Text] [Related]
34. Monocyte-dependent, serum-borne suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patients.
Itoh K; Pellis NR; Balch CM
Cancer Immunol Immunother; 1989; 29(1):57-62. PubMed ID: 2785000
[TBL] [Abstract][Full Text] [Related]
35. Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells.
Rabinowich H; Sedlmayr P; Herberman RB; Whiteside TL
Cell Immunol; 1991 Jul; 135(2):454-70. PubMed ID: 1709827
[TBL] [Abstract][Full Text] [Related]
36. Assessment of in vitro lymphokine activated killer (LAK) cell activity against renal cancer cell lines and its suppression by serum factor using crystal violet assay.
Kanamaru H; Yoshida O
Urol Res; 1989; 17(4):259-64. PubMed ID: 2788951
[TBL] [Abstract][Full Text] [Related]
37. Lymphokine-activated killer cell activity after cryopreservation.
Schmidt-Wolf IG; Aihara M; Negrin RS; Blume KG; Chao NJ
J Immunol Methods; 1989 Dec; 125(1-2):185-9. PubMed ID: 2607152
[TBL] [Abstract][Full Text] [Related]
38. Human recombinant interleukin-4 inhibits lymphokine-activated killer activity of sheep erythrocyte rosette-forming (E+) and -non-forming (E-) human lymphocytes.
Gerosa F; Tommasi M; Gerosa M; Tridente G
Int J Cancer; 1988 Dec; 42(6):902-5. PubMed ID: 3263954
[TBL] [Abstract][Full Text] [Related]
39. Lymphokine-activated killer (LAK) cell phenomenon in cluster headache. "In vitro" activation by recombinant interleukin-2.
Giacovazzo M; Stirparo G; DeStefano L; Martelletti P; Rinaldi-Garaci C
Headache; 1989 Mar; 29(3):177-9. PubMed ID: 2785095
[TBL] [Abstract][Full Text] [Related]
40. Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity.
Brooks B; Rees RC
Clin Exp Immunol; 1988 Nov; 74(2):162-5. PubMed ID: 3265652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]